By

Lundbeckfonden
Cambridge, UK and Indianapolis, US – 15 October 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”) provides an update following receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in respect of its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) on 5 October 2018. “Our discussions...
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October Only issue raised relates to FDA inspection of contract manufacturer of active ingredient No other quality or manufacturing deficiencies noted No clinical safety or efficacy issues identified and no requirement for further clinical studies or data analyses Conference call scheduled for 09.30...
Lund, Sweden, 08:00 CET, 08 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces that its US commercial team will be showcasing CERAMENT®|BONE VOID FILLER (CERAMENT®|BVF) at two important US orthopedic conferences taking place in October. These marketing activities are taking place just ahead of the launch...
Ny metode åbner døren for masseproduktion af slangemodgift uden de mange bivirkninger, der kendetegner dagens produkter. Danske forskere – herunder en Lundbeckfonden Talentpris-modtager – har spillet en vigtig rolle i udviklingsarbejdet. På verdensplan dør omkring 100.000 mennesker hver eneste år, fordi de bliver bidt af giftslanger – mens mindst 400.000 andre, der overlever et bid,...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients...
Lundbeckfondens nye Grants and Prizes-panel er på plads, og de seks internationale topforskere i panelet er klar til at vurdere fondens største hjernesatsninger. Seks topforskere bliver det kritiske kvalitetsfilter, der skal bidrage til at virkeliggøre Lundbeckfondens ambition om, at Danmark skal være en af verdens førende hjerneforsknings-nationer. De seks forskere kommer til at udgøre et...
Lund, Sweden, 18:00 CET 28 September 2018 – During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 September 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,555,917. For more information contact: BONESUPPORT AB Emil...
Forskere fra Københavns Universitet har fået bevillinger på i alt 90 mio. kr. til på forskellige måder at studere hologenomet – samarbejdet mellem et dyrs egen arvemasse og dets tarmbakteriers. Laks og markmus spiller en afgørende rolle i det store forskningsprojekt, der handler om såvel miljø som udvikling af ny medicin. Kan man finde ud...
Lund, Sweden, 08:00 CET, 19 September 2018 – Strategic review has led to important initiatives to strengthen BONESUPPORT’s US and European commercial platforms Excellent progress in creating own distributor network in the US. 18 new distributors contracted. 425 highly motivated sales reps to sell BONESUPPORT’s products from 21 October 2018   European commercial expansion on track...
1 2 3 16

Nyheder

Giftslanger: Forskere finder smart modgift-cocktail
2. oktober 2018
Nyt panel skal udpege Lundbeckfondens største hjernesatsninger
1. oktober 2018
Laks og markmus skal gøre os klogere på gådefuldt hologenom
28. september 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge